Search research articles
Contact Us
Filters
Showing results (41-50 of 78) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, et al.
Breast Cancer Research and Treatment
|
November 21, 2020
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)
Katherine Clifton, Jingqin Luo, Yu Tao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Christopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Cancer
|
June 11, 2016
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
Jeffrey S Ross, Laurie M Gay, Kai Wang, et al.
JAMA Oncology
|
April 15, 2016
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
Ahmad Awada, Ramon Colomer, Kenichi Inoue, et al.
The Lancet. Oncology
|
March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
The Lancet. Oncology
|
August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Biorxiv : the Preprint Server for Biology
|
July 16, 2025
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages
Xiaoqing Cheng, Khooshbu Kantibhai Patel, Brandon Zhou, et al.
Cell
|
September 18, 2012
Genomic landscape of non-small cell lung cancer in smokers and never-smokers
Ramaswamy Govindan, Li Ding, Malachi Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Whitney L Hensing, Lorenzo Gerratana, Katherine Clifton, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 78) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 13, 2025
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Funda Meric-Bernstam, Kanwal Pratap Singh Raghav, Christopher J Sweeney, et al.
Breast Cancer Research and Treatment
|
November 21, 2020
Mutation profile differences in younger and older patients with advanced breast cancer using circulating tumor DNA (ctDNA)
Katherine Clifton, Jingqin Luo, Yu Tao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 4, 2023
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors
Christopher J Sweeney, John D Hainsworth, Ron Bose, et al.
Cancer
|
June 11, 2016
Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
Jeffrey S Ross, Laurie M Gay, Kai Wang, et al.
JAMA Oncology
|
April 15, 2016
Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial
Ahmad Awada, Ramon Colomer, Kenichi Inoue, et al.
The Lancet. Oncology
|
March 13, 2019
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, et al.
The Lancet. Oncology
|
August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Biorxiv : the Preprint Server for Biology
|
July 16, 2025
Cerebellum metastasis model of HER2-positive breast cancer unveils key role of IL34-induced Arg1+ macrophages
Xiaoqing Cheng, Khooshbu Kantibhai Patel, Brandon Zhou, et al.
Cell
|
September 18, 2012
Genomic landscape of non-small cell lung cancer in smokers and never-smokers
Ramaswamy Govindan, Li Ding, Malachi Griffith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
Whitney L Hensing, Lorenzo Gerratana, Katherine Clifton, et al.
Page
of 8